Natixis Advisors LLC Buys 47,437 Shares of Genmab A/S (NASDAQ:GMAB)

Natixis Advisors LLC lifted its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 29.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 206,563 shares of the company's stock after purchasing an additional 47,437 shares during the quarter. Natixis Advisors LLC's holdings in Genmab A/S were worth $5,036,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Oppenheimer Asset Management Inc. boosted its holdings in Genmab A/S by 26.3% during the second quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company's stock valued at $5,480,000 after purchasing an additional 45,376 shares in the last quarter. Choreo LLC acquired a new stake in Genmab A/S in the 2nd quarter valued at $776,000. Renaissance Technologies LLC boosted its stake in Genmab A/S by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company's stock valued at $36,752,000 after buying an additional 103,859 shares in the last quarter. US Bancorp DE grew its position in Genmab A/S by 16.0% in the third quarter. US Bancorp DE now owns 171,669 shares of the company's stock valued at $4,185,000 after acquiring an additional 23,723 shares during the period. Finally, Creative Planning raised its stake in Genmab A/S by 136.3% during the third quarter. Creative Planning now owns 47,422 shares of the company's stock worth $1,156,000 after acquiring an additional 27,353 shares in the last quarter. 7.07% of the stock is owned by institutional investors.

Genmab A/S Stock Performance

Shares of GMAB opened at $20.65 on Friday. The business's fifty day moving average price is $23.16 and its two-hundred day moving average price is $25.91. The firm has a market capitalization of $13.67 billion, a price-to-earnings ratio of 20.05, a PEG ratio of 0.64 and a beta of 0.99. Genmab A/S has a 52 week low of $20.34 and a 52 week high of $32.88.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.03). The firm had revenue of $816.10 million during the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same quarter in the prior year, the business earned $0.47 EPS. As a group, research analysts forecast that Genmab A/S will post 1.28 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Truist Financial lowered their target price on shares of Genmab A/S from $53.00 to $50.00 and set a "buy" rating on the stock in a report on Monday, September 9th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price objective on shares of Genmab A/S in a report on Wednesday, October 16th. Morgan Stanley reissued an "equal weight" rating and issued a $31.00 target price on shares of Genmab A/S in a report on Wednesday, September 11th. JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Genmab A/S in a report on Tuesday, August 20th. Finally, Redburn Atlantic started coverage on Genmab A/S in a research note on Tuesday, October 8th. They issued a "buy" rating on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Genmab A/S has a consensus rating of "Moderate Buy" and an average target price of $45.20.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.